Sevion Therapeutics Inc  

(Public, OTCBB:SVON)   Watch this stock  
Find more results for NYSEAMEX:SNT
0.770
0.000 (0.00%)
Jul 28 - Close
OTCBB data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.51 - 2.15
Open     -
Vol / Avg. 20.00/49,560.00
Mkt cap 12.62M
P/E     -
Div/yield     -
EPS -1.75
Shares 16.39M
Beta 0.51
Inst. own 0%
May 15, 2015
Q3 2015 Sevion Therapeutics Inc Earnings Release
  

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -3272.21% -9225.23%
Operating margin -3266.67% -9147.80%
EBITD margin - -6572.38%
Return on average assets -27.75% -45.63%
Return on average equity -42.85% -88.59%
Employees 25 -
CDP Score - -

Address

4045 Sorrento Valley Blvd
SAN DIEGO, CA 92121-1404
United States - Map
+1-908-8644444 (Phone)
+1-302-6365454 (Fax)

Website links

Description

Sevion Therapeutics, Inc., formerly Senesco Technologies, Inc., is engaged in utilizing technology related to antibody genes, antibody discovery technology, modified cow antibodies, and antibody drug candidates, and certain genes, primarily eukaryotic translation initiation Factor 5A, or Factor 5A, and deoxyhypusine synthase, or DHS, and related technologies for human therapeutic applications to develop novel approaches to treat cancer and inflammatory diseases. The Company’s lead antibody is SVN001. SNS01-T utilizes the Company's Factor 5A technology and consists of two components, which include a DNA plasmid expressing human eIF5A containing a lysine to arginine substitution at amino acid position 50 and a small inhibitory RNA. The agricultural research is focused on the discovery and development of certain gene technologies, which are designed to confer positive traits on fruits, flowers, vegetables, forestry species and agronomic crops.

Officers and directors

Harlan W. Waksal M.D. Chairman of the Board
Age: 60
David S. Rector Interim President, Interim Chief Executive Officer, Director
Age: 68
James R. Schmidt CPA Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
Age: 53
James Graziano Ph.D. Chief Technology Officer
Vaughn Smider M.D., Ph.D. Chief Scientific Officer, Director
Miguel de los Rios Ph.D. Vice President - Research
Phillip Frost M.D. Director
Steven Rubin Director
John N. Braca Independent Director